CD28 and congenital rubella syndrome: The NSG-SGM3 mouse model used by us has previously proven to be more sensitive for CRS than the parental NSG strain when evaluating the safety of anti-CD28 superagonist and anti-PD1 monoclonal antibodies and additionally captures the variation in cytokine release between individual donors (Ye et al, 2020).